Advertisement Boehringer Ingelheim Launches ‘Lean-to-Clinic’ Program for Fast Drug Product Supply - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Boehringer Ingelheim

Drug Substance and Drug Product Services

More info about Boehringer Ingelheim

Boehringer Ingelheim Launches ‘Lean-to-Clinic’ Program for Fast Drug Product Supply

The improved approach combines Boehringer Ingelheim’s automated high throughput technologies in process science with a lean drug development approach to offer cost-effective services with shorter timelines. Within the Boehringer Ingelheim "one-stop-shop" service drug substances for toxicological and clinical studies may be delivered after only 13 months and drug products for clinical studies already after 16 months.

"’Lean to Clinic’ is another milestone of our winning offers strategy to secure technology leadership, flexibility and customer orientation", commented Simon Sturge, Corporate Senior Vice President Biopharmaceuticals at Boehringer Ingelheim. "’Lean to Clinic’ consists of streamlined work packages and significantly speeds up cell line development, phase I process development and preclinical and clinical supplies from mammalian cell cultures."